高明权,牛 毅

脓毒血症是一种危及生命的疾病，其特征是宿主对感染的反应失调，导致器官感染功能障碍。临床上表现无特异性，临床以SOFA评分诊断脓毒血症及判断严重程度，但对于脓毒血症的早期诊断更为重要。虽然qSOFA评分更能早期识别脓毒血症，但存在局限性，近年来生物标志物的研究在对脓毒血症的诊断，器官衰竭、预后的评估有着极大的意义。对生物指标的变化趋势的检测为临床早期诊断脓毒血症及评估预后提供生物学依据。

脓毒血症；生物标志物；诊断

[1] RøSJøH,MASSON S,CAIRONI P,et al.Prognostic Value of Secretoneurin in Patients With Severe Sepsis and Septic Shock:Data From the Albumin Italian Outcome Sepsis Study[J].Crit Care Med,2018,46(5):e404-e10. [2] Y U M H,CHEN M H,HAN F,et al.Prognostic value of the biomarkers serum amyloid A and nitric oxide in patients with sepsis[J].Int Immunopharmacol,2018,62:287-92. [3] SEYMOUR C W,KENNEDY J N,WANG S,et al.Derivation,Validation,and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis[J].Jama,2019,321(20):2003-17. [4] CECCONI M,EVANS L,LEVY M,et al.Sepsis and septic shock[J].Lancet,2018,392(10141):75-87. [5] MASSON S,CAIRONI P,SPANUTH E,et al.Presepsin(soluble CD14 subtype)and procalcitonin levels for mortality prediction in sepsis:data from the Albumin Italian Outcome Sepsis trial[J].Crit Care,2014,18(1):R6. [6] NAPOLITANO L M.Sepsis 2018:Definitions and Guideline Changes[J].Surg Infect(Larchmt),2018,19(2):117-25. [7] FLEISCHMANN-STRUZEK C,MELLHAMMAR L,ROSE N,et al.Incidence and mortality of hospital-and ICU-treated sepsis:results from an updated and expanded systematic review and meta-analysis[J].Intensive Care Med,2020,46(8):1552-62. [8] SINGER M,DEUTSCHMAN C S,SEYMOUR C W,et al.The Third International Consensus Definitions for Sepsis and Septic Shock(Sepsis-3)[J].Jama,2016,315(8):801-10. [9] SEYMOUR C W,LIU V X,IWASHYNA T J,et al.Assessment of Clinical Criteria for Sepsis:For the Third International Consensus Definitions for Sepsis and Septic Shock(Sepsis-3)[J].Jama,2016,315(8):762-74. [10] RAITH E P,UDY A A,BAILEY M,et al.Prognostic Accuracy of the SOFA Score,SIRS Criteria,and qSOFA Score for In-Hospital Mortality Among Adults With Suspected Infection Admitted to the Intensive Care Unit[J].JAMA,2017,317(3):290-300. [11] RHODES A,EVANS L E,ALHAZZANI W,et al.Surviving Sepsis Campaign:International Guidelines for Management of Sepsis and Septic Shock:2016[J].Intensive Care Med,2017,43(3):304-77. [12] PHUA J,NGERNG W,SEE K,et al.Characteristics and outcomes of culture-negative versus culture-positive severe sepsis[J].Crit Care,2013,17(5):R202. [13] VINCENT J-L,SAKR Y,SINGER M,et al.Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017[J].JAMA,2020,323(15):1478-87. [14] BALDIRàJ,RUIZ-RODRíGUEZ J C,RUIZ-SANMARTIN A,et al.Use of Biomarkers to Improve 28-Day Mortality Stratification in Patients with Sepsis and SOFA≤6[J].Biomedicines,2023,11(8). [15] MéNDEZ HERNáNDEZ R,RAMASCO RUEDA F.Biomarkers as Prognostic Predictors and Therapeutic Guide in Critically Ill Patients:Clinical Evidence[J].J Pers Med,2023,13(2). [16] SANZ CODINA M,ZEITLINGER M.Biomarkers Predicting Tissue Pharmacokinetics of Antimicrobials in Sepsis:A Review[J].Clin Pharmacokinet,2022,61(5):593-617. [17] DIX C,ZELLER J,STEVENS H,et al.C-reactive protein,immunothrombosis and venous thromboembolism[J].Front Immunol,2022,13:1002652. [18] MCFADYEN J D,ZELLER J,POTEMPA L A,et al.C-Reactive Protein and Its Structural Isoforms:An Evolutionary Conserved Marker and Central Player in Inflammatory Diseases and Beyond[J].Subcell Biochem,2020,94:499-520. [19] PóVOA P,SALLUH J I.Biomarker-guided antibiotic therapy in adult critically ill patients:a critical review[J].Ann Intensive Care,2012,2(1):32. [20] PARLATO M,PHILIPPART F,ROUQUETTE A,et al.Circulating biomarkers may be unable to detect infection at the early phase of sepsis in ICU patients:the CAPTAIN prospective multicenter cohort study[J].Intensive Care Med,2018,44(7):1061-70. [21] PIERRAKOS C,VELISSARIS D,BISDORFF M,et al.Biomarkers of sepsis:time for a reappraisal[J].Crit Care,2020,24(1):287. [22] MIERZCHAŁA-PASIERB M,LIPIŃSKA-GEDIGA M.Sepsis diagnosis and monitoring-procalcitonin as standard,but what next?[J].Anaesthesiol Intensive Ther,2019,51(4):299-305. [23] LARGMAN-CHALAMISH M,WASSERMAN A,SILBERMAN A,et al.Differentiating between bacterial and viral infections by estimated CRP velocity[J].PLoS One,2022,17(12):e0277401. [24] MAVES R C,ENWEZOR C H.Uses of Procalcitonin as a Biomarker in Critical Care Medicine[J].Infect Dis Clin North Am,2022,36(4):897-909. [25] PóVOA P,COELHO L,DAL-PIZZOL F,et al.How to use biomarkers of infection or sepsis at the bedside:guide to clinicians[J].Intensive Care Med,2023,49(2):142-53. [26] ZAKI H A,BENSLIMAN S,BASHIR K,et al.Accuracy of procalcitonin for diagnosing sepsis in adult patients admitted to the emergency department:a systematic review and meta-analysis[J].Syst Rev,2024,13(1):37. [27] LI S,RONG H,GUO Q,et al.Serum procalcitonin levels distinguish Gram-negative bacterial sepsis from Gram-positive bacterial and fungal sepsis[J].Journal of Research in Medical Sciences,2016,21(1):39. [28] CHEN J,TU X,HUANG M,et al.Prognostic value of platelet combined with serum procalcitonin in patients with sepsis[J].Medicine(Baltimore),2023,102(34):e34953. [29] OLIVEIRA C F,BOTONI F A,OLIVEIRA C R,et al.Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis:a randomized trial[J].Crit Care Med,2013,41(10):2336-43. [30] HENNING D J,HALL M K,WATSJOLD B K,et al.Interleukin-6 improves infection identification when added to physician judgment during evaluation of potentially septic patients[J].Am J Emerg Med,2020,38(5):947-52. [31] HU P,CHEN Y,PANG J,et al.Association between IL-6 polymorphisms and sepsis[J].Innate Immun,2019,25(8):465-72. [32] KANG R,CHEN R,ZHANG Q,et al.HMGB1 in health and disease[J].Mol Aspects Med,2014,40:1-116. [33] HARRIS H E,ANDERSSON U,PISETSKY D S.HMGB1:a multifunctional alarmin driving autoimmune and inflammatory disease[J].Nat Rev Rheumatol,2012,8(4):195-202. [34] DENG C,ZHAO L,YANG Z,et al.Targeting HMGB1 for the treatment of sepsis and sepsis-induced organ injury[J].Acta Pharmacol Sin,2022,43(3):520-8. [35] MA K,ZHANG Y,HAO J,et al.Correlation analysis of systemic immune inflammatory index,Serum IL-35 and HMGB-1 with the severity and prognosis of sepsis[J].Pak J Med Sci,2023,39(2):497-501. [36] LU B,ZHANG Y,LI C,et al.The utility of presepsin in diagnosis and risk stratification for the emergency patients with sepsis[J].Am J Emerg Med,2018,36(8):1341-5. [37] ENGUIX-ARMADA A,ESCOBAR-CONESA R,GARCíA-DE LA TORRE A,et al.Usefulness of several biomarkers in the management of septic patients:C-reactive protein,procalcitonin,presepsin and mid-regional pro-adrenomedullin[J].Clin Chem Lab Med,2016,54(1):163-8. [38] LELI C,FERRANTI M,MARRANO U,et al.Diagnostic accuracy of presepsin(sCD14-ST)and procalcitonin for prediction of bacteraemia and bacterial DNAaemia in patients with suspected sepsis[J].J Med Microbiol,2016,65(8):713-9. [39] PRAZAK J,IRINCHEEVA I,LLEWELYN M J,et al.Accuracy of pancreatic stone protein for the diagnosis of infection in hospitalized adults:a systematic review and individual patient level meta-analysis[J].Crit Care,2021,25(1):182. [40] KLEIN H J,NIGGEMANN P,BUEHLER P K,et al.Pancreatic Stone Protein Predicts Sepsis in Severely Burned Patients Irrespective of Trauma Severity:A Monocentric Observational Study[J].Ann Surg,2021,274(6):e1179-e86. [41] PUGIN J,DAIX T,PAGANI J L,et al.Serial measurement of pancreatic stone protein for the early detection of sepsis in intensive care unit patients:a prospective multicentric study[J].Crit Care,2021,25(1):151. [42] VELISSARIS D,ZAREIFOPOULOS N,KARAMOUZOS V,et al.Presepsin as a Diagnostic and Prognostic Biomarker in Sepsis[J].Cureus,2021,13(5):e15019. [43] LIANG J,CAI Y,SHAO Y.Comparison of presepsin and Mid-regional pro-adrenomedullin in the diagnosis of sepsis or septic shock:a systematic review and meta-analysis[J].BMC Infect Dis,2023,23(1):288. [44] AZIM A.Presepsin:A Promising Biomarker for Sepsis[J].Indian J Crit Care Med,2021,25(2):117-8. [45] RUANGSOMBOON O,PANJAIKAEW P,MONSOMBOON A,et al.Diagnostic and prognostic utility of presepsin for sepsis in very elderly patients in the emergency department[J].Clin Chim Acta,2020,510:723-32. [46] XINI A,PISTIKI A,LADA M,et al.Association of the early absolute CD64-expressing neutrophil count and sepsis outcome[J].Eur J Clin Microbiol Infect Dis,2019,38(6):1123-8. [47] CONG S,MA T,DI X,et al.Diagnostic value of neutrophil CD64,procalcitonin,and interleukin-6 in sepsis:a meta-analysis[J].BMC Infect Dis,2021,21(1):384. [48] ZHOU Y,ZHANG Y,JOHNSON A,et al.Combined CD25,CD64,and CD69 biomarker panel for flow cytometry diagnosis of sepsis[J].Talanta,2019,191:216-21. [49] HUANG N,CHEN J,WEI Y,et al.Multi-marker approach using C-reactive protein,procalcitonin,neutrophil CD64 index for the prognosis of sepsis in intensive care unit:a retrospective cohort study[J].BMC Infect Dis,2022,22(1):662. [50] JIANG S,LIU L,ZHU X.Correlation of serum H-FABP,sTREM-1,and HMGB1 levels with severity and prognosis of sepsis[J].Am J Transl Res,2024,16(10):5846-55. [51] DERIVE M,GIBOT S.Urine sTREM-1 assessment in diagnosing sepsis and sepsis-related acute kidney injury[J].Crit Care,2011,15(6):1013. [52] BELTRáN-GARCíA J,OSCA-VERDEGAL R,NACHER-SENDRA E,et al.Circular RNAs in Sepsis:Biogenesis,Function,and Clinical Significance[J].Cells,2020,9(6). [53] JUN L,WANG Z,WANG S,et al.Circular RNAs as potential biomarkers for male severe sepsis[J].Open Life Sci,2024,19(1):20220900. [54] TIAN C,LIU J,DI X,et al.Exosomal hsa_circRNA_104484 and hsa_circRNA_104670 may serve as potential novel biomarkers and therapeutic targets for sepsis[J].Sci Rep,2021,11(1):14141. [55] LIU H C,HAN D S,HSU C C,et al.Circulating MicroRNA-486 and MicroRNA-146a serve as potential biomarkers of sarcopenia in the older adults[J].BMC Geriatr,2021,21(1):86. [56] SUN B,GUO S.miR-486-5p Serves as a Diagnostic Biomarker for Sepsis and Its Predictive Value for Clinical Outcomes[J].J Inflamm Res,2021,14:3687-95. [57] BINDAYNA K.MicroRNA as Sepsis Biomarkers:A Comprehensive Review[J].Int J Mol Sci,2024,25(12).

点击下载PDF